Correspondence 0001213900-26-040821 from RELMADA THERAPEUTICS, INC. (RLMD)
RELMADA THERAPEUTICS, INC.
Date: April 7, 2026 · CIK: 0001553643 · Accession: 0001213900-26-040821
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294885
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance File No. 333-294885 Acceleration Request Requested Date: April 9, 2026 Requested Time: 4:05 p.m., Eastern Time
Re: Relmada Therapeutics, Inc.
Dear Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Relmada Therapeutics, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.
Please call Tracy Buffer of Lowenstein Sandler LLP at (973) 597-2434 to confirm the effectiveness of the Registration Statement or with any questions.
Sincerely,
RELMADA THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
April 7, 2026
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Relmada Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-294885
Acceleration Request
Requested Date:
April 9, 2026
Requested Time:
4:05 p.m., Eastern Time
Dear Ladies and Gentlemen:
Pursuant to Rule 461
under the Securities Act of 1933, as amended, Relmada Therapeutics, Inc. (the “Company”) hereby requests that the above-referenced
Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the
“Commission”) at the “Requested Date” and “Requested Time” set forth above or at such later time as
the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.
Please call Tracy Buffer of Lowenstein Sandler
LLP at (973) 597-2434 to confirm the effectiveness of the Registration Statement or with any questions.
Sincerely,
RELMADA THERAPEUTICS, INC.
By:
/s/ Sergio Traversa
Name:
Sergio Traversa
Title:
Chief Executive Officer